Morgan Stanley downgraded Qiagen (QGEN) to Equal Weight from Overweight with a $48 price target The firm also upgrade the medical technology sector view to Attractive from In-line. However, Morgan ...

Morgan Stanley upgraded Qiagen (NYSE:QGEN) to Overweight from Equal-Weight and raised its price target to $51.00 from $49.48 per share on Friday, citing a valuation disconnect between the Dutch ...

Morgan Stanley analyst Robert Davies downgraded Qiagen (QGEN - Research Report) to a Hold today and set a price target of EUR49.00. The companys shares closed yesterday at $44.63. According to ...